BACKGROUND: Osteosarcoma (OS) is an aggressive bone malignancy that primarily affects children and adolescents. Patients with metastatic disease at diagnosis have only a 20% survival rate. The poor survival rate of these patients is largely due to their lack of responsiveness to chemotherapy. However, the mechanisms underlying osteosarcoma chemoresistance remain unknown. MATERIALS AND METHODS: The effect of cisplatin, doxorubicin and etoposide was examined on OS cell lines. Affymetric Genechip analysis was used to examine differential gene expression. RESULTS: A correlation between increasing metastatic potential and increasing chemoresistance was observed in the MG-63 cell line and sub-line model. Microarray analysis of these cell lines revealed the differential expression of several genes potentially involved in chemoresistance including ABCG2, ADD3, NMT2, WNTSa and PTN. CONCLUSION: The identification of genes contributing to chemoresistance and determining the role these genes play is critical in characterizing patient responsiveness and overcoming chemoresistance in osteosarcoma patients.
BACKGROUND:Osteosarcoma (OS) is an aggressive bone malignancy that primarily affects children and adolescents. Patients with metastatic disease at diagnosis have only a 20% survival rate. The poor survival rate of these patients is largely due to their lack of responsiveness to chemotherapy. However, the mechanisms underlying osteosarcoma chemoresistance remain unknown. MATERIALS AND METHODS: The effect of cisplatin, doxorubicin and etoposide was examined on OS cell lines. Affymetric Genechip analysis was used to examine differential gene expression. RESULTS: A correlation between increasing metastatic potential and increasing chemoresistance was observed in the MG-63 cell line and sub-line model. Microarray analysis of these cell lines revealed the differential expression of several genes potentially involved in chemoresistance including ABCG2, ADD3, NMT2, WNTSa and PTN. CONCLUSION: The identification of genes contributing to chemoresistance and determining the role these genes play is critical in characterizing patient responsiveness and overcoming chemoresistance in osteosarcomapatients.
Authors: Bernd Kubista; Florian Klinglmueller; Martin Bilban; Martin Pfeiffer; Richard Lass; Alexander Giurea; Phillipp T Funovics; Cyril Toma; Martin Dominkus; Rainer Kotz; Theresia Thalhammer; Klemens Trieb; Teresa Zettl; Christian F Singer Journal: Int Orthop Date: 2010-03-26 Impact factor: 3.075
Authors: Daniel G Fuja; Nino C Rainusso; Ryan L Shuck; Lyazat Kurenbekova; Lawrence A Donehower; Jason T Yustein Journal: Am J Cancer Res Date: 2018-09-01 Impact factor: 6.166
Authors: K E Holmes; V Thompson; C M Piskun; R A Kohnken; M K Huelsmeyer; T M Fan; T J Stein Journal: Vet Comp Oncol Date: 2013-03-12 Impact factor: 2.613
Authors: Gayathri T Selvarajah; Jolle Kirpensteijn; Monique E van Wolferen; Nagesha A S Rao; Hille Fieten; Jan A Mol Journal: Mol Cancer Date: 2009-09-07 Impact factor: 27.401